Precision Medicine News and Research

RSS

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

NIH funding helps to boost sales of DNA sequencers

Rapid increase in output from second-generation DNA sequencers has enabled new levels of productivity and new experiments. This, along with funding from the stimulus bill, has caused rapid adoption of these machines, according to healthcare market research firm Kalorama Information, helping to fuel sales of DNA sequencers to $480 million in 2008. In its report "DNA Sequencing Equipment and Services Markets, 2nd Edition," Kalorama says more changes are on the way and will drives sales growth of 19% annually through 2013.

23 Sep 2009

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

Oncotype DX Recurrence Score provides consistent results across varied patient populations

Genomic Health, Inc. today, announced results from the first study to compare the distribution of Oncotype DX® Recurrence Score® results between European, Middle Eastern and United States patient populations.

22 Sep 2009

Researcher can anticipate immune response in Alzheimer's patients

A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients. This continuing research at Ben-Gurion University of the Negev could one day lead to specific Alzheimer's vaccines that reduce plaque, neuronal damage and inflammation associated with the disease.

22 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Raindance Technologies and CLC to develop software for resequencing analysis

RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next generation DNA sequencing platforms.

18 Sep 2009

National Research Council's report emphasizes on launching of a new multidisciplinary initiative

A report released today by the National Research Council calls on the United States to launch a new multiagency, multiyear, and multidisciplinary initiative to capitalize on the extraordinary advances recently made in biology and to accelerate new breakthroughs that could solve some of society's most pressing problems -- particularly in the areas of food, environment, energy, and health.

18 Sep 2009

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

16 Sep 2009

iMedicor and Transgenomic to develop an educational marketing program for NuroPro

iMedicor and Transgenomic today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic’s diagnostic tests for Alzheimer’s and Parkinson’s disease.

15 Sep 2009

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

15 Sep 2009

HFSA annual meeting features discussion on David Duncan's quest for personalized medicine

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion by David Ewing Duncan titled "One Man's Quest for Personalized Medicine." Over the course of one year, Duncan submitted himself to hundreds of tests that could predict and even prevent future illness.

14 Sep 2009

Knowledge gap regarding the use of breast cancer tests

A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin).

14 Sep 2009

Aperio Technologies forges alliance with HistoRx to provide an integrated whole-slide imaging system

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, and HistoRx, Inc., (HistoRx), a leader in the emerging field of tissue-based assays for targeted patient treatment, have entered into a partnership to provide an integrated solution for whole-slide imaging with fluorescence.

10 Sep 2009

Dana-Farber Cancer Institute reaches milestone: $1 billion raised in campaign

Dana-Farber Cancer Institute today announced it has reached its $1 billion Mission Possible: The Dana-Farber Campaign to Conquer Cancer fundraising goal one year early. The first hospital in New England to set and reach a $1 billion campaign goal, Dana-Farber will continue to raise funds for campaign priorities until Sept. 30, 2010, when the campaign was scheduled to end.

9 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin((R)) (trastuzumab)*, a personalized medicine therapy, which was the first to target a specific type of breast cancer.

8 Sep 2009

IRS1 gene could lead to better treatment of type 2 diabetes

A breakthrough by an international team of researchers in Canada, France, the UK and Denmark has uncovered a new gene that could lead to better treatment of type 2 diabetes, as well as a better understanding of how this widespread disease develops.

7 Sep 2009

Advisory company focused on the development of personalized medicine launched

Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels.

7 Sep 2009

Precision Medicine News and Research

Misregulation of SPAK protein may contribute to B-cell lymphoma development

NIH funding helps to boost sales of DNA sequencers

Celera and Medco collaborate in KIF6 gene variant testing

Oncotype DX Recurrence Score provides consistent results across varied patient populations

Researcher can anticipate immune response in Alzheimer's patients

Health Discovery Corporation appoints new COO

Research program to study personalized medicine

Raindance Technologies and CLC to develop software for resequencing analysis

National Research Council's report emphasizes on launching of a new multidisciplinary initiative

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

iMedicor and Transgenomic to develop an educational marketing program for NuroPro

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

HFSA annual meeting features discussion on David Duncan's quest for personalized medicine

Knowledge gap regarding the use of breast cancer tests

Aperio Technologies forges alliance with HistoRx to provide an integrated whole-slide imaging system

Dana-Farber Cancer Institute reaches milestone: $1 billion raised in campaign

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Axel Ullrich receives the 2009 Dr. Paul Janssen Award for Biomedical Research

IRS1 gene could lead to better treatment of type 2 diabetes

Advisory company focused on the development of personalized medicine launched

Event guide: The 4th Precision Medicine in Inflammatory Bowel Disease Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News